5 results about "Myocyte proliferation" patented technology

The invention relates to application of an FGFBP2 gene in regulation and control of growth and development and cell cycle of chicken skeletal muscle. The inventor finds the existence of the FGFBP2 gene in early-stage work of a team, and also finds that the expression quantity difference of the gene in muscular tissues of chickens in different development stages and varieties is obvious. In order to further reveal the effect of the FGFBP2 gene in the growth and development process of chicken skeletal muscles, the FGFBP2 gene is overexpressed in chicken myoblasts and AA broiler chickens respectively by using an overexpression technology, and detection finds that the overexpressed FGFBP2 gene can promote the proliferation of myoblasts. The discovery that the FGFBP2 gene can regulate and control the proliferation function of the chicken skeletal muscle cells provides a new theoretical basis for revealing the development of the chicken skeletal muscle and improving the meat production character, and provides a new thought for improving the meat production performance of livestock.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

This invention relates to the field of biomimetic nanozymes and their preparation technology, disclosing a biomimetic nanozyme, its preparation method, and its applications. A peptide-functionalized biomimetic nanozyme (HRPL) is obtained by loading rapamycin onto HMPB nanozymes, coating the surface with a platelet membrane, and functionalizing it with the integrin-binding peptide LXW7. The binding of the platelet membrane to the LXW7 peptide enables targeted delivery to the site of endothelial injury, promoting endothelial repair and re-epithelialization. In an acidic inflammatory microenvironment, HRPL releases rapamycin, inhibiting smooth muscle cell proliferation and migration, and preventing restenosis. HRPL also scavenges reactive oxygen species, reducing oxidative stress and local inflammation, thereby improving the vascular microenvironment. The therapeutic effect was evaluated using a typical rat carotid balloon injury model. This dual-targeting mechanism not only promotes endothelial repair but also reduces restenosis and inflammation, showing significant clinical therapeutic potential. Especially after stent implantation, HRPL helps improve prognosis, reduce complications, and restore vascular homeostasis.

The application belongs to the technical field of medicine, and discloses a kind of oxaevodiamine compounds and pharmaceutical use thereof, and specifically provides a kind of oxaevodiamine compounds shown in formula (I), and their physiologically acceptable salts and pharmaceutical compositions.The compounds can effectively inhibit the proliferation of pulmonary artery smooth muscle cells caused by PDGF-BB, and can be used for preventing or treating pulmonary arterial hypertension.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and / or hypertrophy, an agent for increasing muscle mass and / or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.